Compare Abbott Laboratories (ABT) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Kyndryl Holdings Inc — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Kyndryl Holdings Inc trades at $11.96 (market cap $2.73B). The key difference: Abbott Laboratories is far larger — about 61.2× Kyndryl Holdings Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| ABT | KD | |
|---|---|---|
Market Cap | $166.94B | $2.73B |
Sector | Health | Technology |
52-Week High | $136.62 | $43.38 |
52-Week Low | $82.57 | $10.59 |
Enterprise Value | $193.69B | $5.07B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Kyndryl Holdings (KD) trades at $12.39, up 1.14% on the day, with a bullish technical signal from moving averages. The company reported revenue of $15.06B for 2025, achieving a net income of $252M, marking a return to profitability after losses in prior years. Recent news includes a partnership with Microsoft for sovereignty solutions and new executive appointments, but also legal investigations into the company's disclosures following a significant stock price decline earlier in 2026.
The outlook is mixed; improving cash flow and a low EV/EBITDA of 3.19 suggest undervaluation, but recent earnings misses and legal overhangs pose risks. Analyst consensus is a 'Hold' with a $14.33 price target, implying modest upside. Key investor focus is on the Q2 2026 earnings report due August 5, 2026, for confirmation of the profitability turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
